组胺及其受体配体在青光眼和视网膜神经保护中的新见解。
Novel Insight of Histamine and Its Receptor Ligands in Glaucoma and Retina Neuroprotection.
机构信息
Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy.
Toxicology Unit, Emergency Department, Careggi University Hospital, 50139 Florence, Italy.
出版信息
Biomolecules. 2021 Aug 11;11(8):1186. doi: 10.3390/biom11081186.
Glaucoma is a multifactorial neuropathy characterized by increased intraocular pressure (IOP), and it is the second leading cause of blindness worldwide after cataracts. Glaucoma combines a group of optic neuropathies characterized by the progressive degeneration of retinal ganglionic cells (RGCs). Increased IOP and short-term IOP fluctuation are two of the most critical risk factors in glaucoma progression. Histamine is a well-characterized neuromodulator that follows a circadian rhythm, regulates IOP and modulates retinal circuits and vision. This review summarizes findings from animal models on the role of histamine and its receptors in the eye, focusing on the effects of histamine H receptor antagonists for the future treatment of glaucomatous patients.
青光眼是一种多因素的神经病变，其特征是眼内压（IOP）升高，它是继白内障之后全球第二大致盲原因。青光眼是一组视神经病变的统称，其特征是视网膜神经节细胞（RGCs）的进行性退化。IOP 升高和短期 IOP 波动是青光眼进展的两个最关键的危险因素。组胺是一种特征明确的神经调节剂，具有昼夜节律，调节 IOP 并调节视网膜回路和视力。本综述总结了动物模型中组胺及其受体在眼睛中的作用的研究结果，重点介绍了组胺 H 受体拮抗剂在未来治疗青光眼患者方面的应用。
Zotero 插件